Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved audited standalone financial results for Q4 and FY ended March 31, 2025. Full-year revenue from operations fell sharply to Rs 50.12 lakhs from Rs 113.09 lakhs in FY24, a drop of roughly 56%. Despite the revenue decline, the company swung to a small profit of Rs 2.54 lakhs for the year (vs Rs 3.02 lakhs in FY24), aided by lower expenses. Q4 FY25 saw PAT of Rs 6.29 lakhs compared to a Rs 23.15 lakh loss in the year-ago quarter, with Rs 2.13 lakhs shown as exceptional items. Other equity remains deeply negative at Rs (491.01) lakhs and total assets shrank to Rs 65.25 lakhs from Rs 93.35 lakhs. The statutory auditor issued an unmodified (unqualified) opinion, and the company has no qualified borrowings.
Sharp revenue contraction and persistently negative reserves are red flags for shareholders, though the small profit and clean auditor opinion prevent an immediate crisis. The stock is likely to see limited positive reaction given the weak top-line and tiny earnings base.